INVENTISBIO
InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company is co-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
INVENTISBIO
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2013-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.inventisbio.com
Total Employee:
1+
Status:
Active
Total Funding:
247 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API WordPress Wordpress Plugins Nginx Euro Microsoft Exchange Online
Similar Organizations
Genevide
Genevide is a biotech company that specializes in gene research and development.
New Amsterdam Pharma
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Teligene
Teligene is a drug discovery company edicating to developing innovative small-molecule drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Dyee Capital
Dyee Capital investment in Series D - InventisBio
Janchor Partners
Janchor Partners investment in Series D - InventisBio
Qiming Venture Partners
Qiming Venture Partners investment in Series D - InventisBio
E Fund Management Co.,LTD.
E Fund Management Co.,LTD. investment in Series D - InventisBio
Pudong Innotek
Pudong Innotek investment in Series D - InventisBio
Matrix Partners China
Matrix Partners China investment in Series D - InventisBio
Lilly Asia Ventures
Lilly Asia Ventures investment in Series D - InventisBio
GL Ventures
GL Ventures investment in Series D - InventisBio
CMB International Capital Corporation
CMB International Capital Corporation investment in Series D - InventisBio
Advantech Capital
Advantech Capital investment in Series D - InventisBio
Official Site Inspections
http://www.inventisbio.com
- Host name: 139.224.229.15
- IP address: 139.224.229.15
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "InventisBio"
InventisBio - Crunchbase Company Profile & Funding
InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively …See details»
益方生物科技（上海）股份有限公司
益方生物是一家立足中国具有全球视野的创新型药物研发企业。公司的产品主要聚焦于肿瘤、代谢及自身免疫性疾病等重大 ...See details»
management-team-en – 益方生物科技（上海）股份有限公司
Prior to founding InventisBio, Dr. Wang worked for nearly two decades at multinational pharmaceutical companies. He received his bachelor's degree from Shanghai Medical …See details»
InventisBio Company Description - Stock Analysis
2 days ago Company profile for InventisBio Co., Limited (SHA: 688382) with a description, list of executives, contact details and other key facts.See details»
InventisBio Co., Ltd Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for InventisBio Co., Ltd of Shanghai, Shanghai. Get the latest business insights from Dun & Bradstreet.See details»
InventisBio Company Profile 2024: Stock Performance …
InventisBio Co Ltd is an innovative drug research and development enterprise based in China with a global perspective, focusing on major diseases such as tumors and metabolic diseases. It has independently developed a series of …See details»
InventisBio - Funding, Financials, Valuation & Investors - Crunchbase
InventisBio is registered under the ticker SSE:688382 . Their stock opened with CN¥18.12 in its Jul 24, 2022 IPO. Stock Symbol SSE:688382 ; Valuation at IPO CN¥10.4B; Money Raised at …See details»
InventisBio Company Profile - Office Locations, Competitors ... - Craft
InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer, and gout. The Company is also actively …See details»
InventisBio, Co., Ltd. (益方生物科技（上海）股份有限公司) - 药物 …
了解InventisBio, Co., Ltd. (益方生物科技（上海）股份有限公司)公司的药物管线，治疗领域，技术平台，以及它的42项临床试验, 480篇新闻和10篇文献，疾病领域:肿瘤，内分泌与代谢疾病， …See details»
InventisBio Co Ltd, 688382:SHH profile - FT.com - Financial Times
InventisBio Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main product is still in clinical development. The …See details»
InventisBio - Contacts, Employees, Board Members, Advisors
Organization. InventisBio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Contacts 5. About. InventisBio has 2 current employee profiles, including …See details»
InventisBio Announces $147 Million Series D Financing Led by …
Sep 27, 2020 InventisBio is a fast-growing innovative biotech company, co-founded by Dr. Yaolin Wang and other senior scientists. The company's top management team members …See details»
Chinese Drug Manufacturer InventisBio Bags $147m Led by …
Sep 29, 2020 It had also partnered state-owned Sinopharm Capital to invest $11 million in InventisBio’s Series A round in 2016. Beijing-based financial institution China Renaissance …See details»
InventisBio secures $147m in Series D funding round
Sep 28, 2020 InventisBio, which develops small molecule drugs, currently has three candidates in the mid to late-stage clinical development. One of its new products progressed to a Phase I …See details»
InventisBio Completes $147 Million Round for Small-Molecule Drugs
Sep 28, 2020 InventisBio, a Shanghai company developing novel small molecule drugs, completed a $147 million series D financing led by GL Ventures, a Hillhouse affiliate. It has …See details»
Clinical stage biotech company InventisBio closes $70m Series C ...
This round of investment was co-led by Advantech Capital and CMBI, followed by Pudong Innotek. Also participating were existing investors Lilly Asia Venture (LAV) and OrbiMed Asia. …See details»
KRAS inhibitors by BI and InventisBio have LoA scores rise
Jun 8, 2021 Boehringer Ingelheim’s pan-KRAS inhibitor BI-1701963 and InventisBio’s KRAS G12C inhibitor D-1553 saw their respective Likelihood of Approval (LoA) scores jump by 20 …See details»
Medidata and InventisBio Extend Collaboration with Enterprise …
Sep 27, 2022 Medidata, a Dassault Systèmes company and a leading global provider of cloud-based solutions for life sciences clinical research, and InventisBio recently announced a …See details»
InventisBio Reported Promising Phase I Study Results of a Novel …
SHANGHAI, April 11, 2022 /PRNewswire/ -- InventisBio Co., Ltd., a clinical-stage biotech company based in Shanghai, China has published the clinical data of their oral KRAS G12C …See details»